ELEV

Elevation Oncology, Inc.

2.42 USD
-0.03 (-1.22%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Elevation Oncology, Inc. stock is down -36.81% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 13 June’s closed higher than May. 100% of analysts rate it a buy.

About Elevation Oncology, Inc.

Elevation Oncology focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial.